Seraphina Therapeutics: Company Market Research Report

Company Overview

• Name: Seraphina Therapeutics

• Mission: Seraphina Therapeutics advances nature and food-based science into evidence-driven consumer products that safely support healthier lives. The company focuses on developing products that replenish essential micronutrients and metabolites crucial for health, particularly as individuals age.

• Founders:

• Stephanie Venn-Watson, DVM, MPH - Co-Founder, Chief Executive Officer

• Eric Venn-Watson, MD, MBA - Co-Founder, Chief Operating Officer

• Kim Kamdar, PhD - Co-Founder, Board Chair

• Nicholas Schork, PhD - Co-Founder, Senior Scientist

• Key People:

• Stephanie Venn-Watson, Chief Executive Officer

• Eric Venn-Watson, Chief Operating Officer

• Kim Kamdar, Board Chair

• Nicholas Schork, Senior Scientist

• Edward Dennis, Scientific Advisor

• Ronald Krauss, Scientific Advisor

• Headquarters: No information is available

• Number of Employees: No information is available

• Revenue: No information is available

• Known For: Seraphina Therapeutics is noted for the scientific discovery and promotion of C15:0 (pentadecanoic acid), a newly discovered essential fatty acid considered vital for health maintenance.

Products

Fatty15

• Description: Fatty15 is the world’s first and only science-backed, patented, award-winning supplement based on C15:0. It aims to support long-term health and wellness.

• Key Features:

• Science-backed formulation

• Patented and award-winning

• Supports long-term health and wellness

Recent Developments

• New Discoveries:

• C15:0 has been recognized as the first essential fatty acid discovered in 90 years. This discovery emphasizes the role of C15:0 in promoting cellular health, reducing aging, and supporting various health benefits, including cardiometabolic, immune, and liver health.

• Publications and Innovations:

• Stephanie Venn-Watson's Publications:

• Noteworthy studies, including those published in high-impact journals like PLOS ONE and Sci Rep, demonstrate the diverse health benefits of C15:0.

• Literature:

• Current research highlights the broader activities of pentadecanoic acid compared to omega-3, evaluating its potential for supporting physical and mental health.

• Partnerships and Leadership:

• The company's scientific advisory board consists of prominent figures in lipid research and health sciences, including Dr. Edward Dennis and Dr. Ronald Krauss.

• The blend of academic and practical experience among the key personnel and scientific advisors enhances the credibility and potential for innovative breakthroughs at Seraphina Therapeutics.

• Publications:

• Notable research contributions in journals such as Sci Rep, PLOS ONE, and PNAS, showcasing the health implications and therapeutic roles of C15:0 in various systemic conditions.

Contact Information

• Email: [info@seraphinatherapeutics.com](mailto:info@seraphinatherapeutics.com)

For more information about Seraphina Therapeutics and its products, please refer to their official communications and website content.